RxDoctor Payments DataLook up a doctor →

Marcelo Correia, MD

Endocrinology, Diabetes & Metabolism · Iowa City, IANPI 1235421140

Payments from drug & device makers

$1,544,853in general payments, 2019–2025

Across 365 payments — averaging $4232.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$750K
  • Eli Lilly$497K
  • Novo Nordisk AS$285K
  • Novo Nordisk$7K
  • Pfizer$5K
  • Boston Scientific$149
  • plus $236 from 4 others
$10,789in research payments, 2019–2025

Across 13 payments — averaging $829.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K
  • Novo Nordisk AS$2K

What the payments were for

  • Consulting fees$7,13875%
  • Travel & lodging$1,03511%
  • Food & beverage$1,17012%
  • Education$2262%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis25$750,212
Eli Lilly18$497,017
Novo Nordisk AS300$284,767
Novo Nordisk15$7,471
Pfizer1$5,000
Boston Scientific2$149
Ionis Pharmaceuticals, Inc.1$90
Abbott1$68
Medtronic1$60
Dexcom, Inc.1$19

How this compares

$1,544,853 in reported general payments places this provider in the 95th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.

See all endocrinology, diabetes & metabolism providers in Iowa

Medicare billing

Part B allowed, 2024
$32,857
Medicare patients
190
Services billed
416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab106$69,976
MounjaroTirzepatide58$57,679
OzempicSemaglutide41$52,887
Praluent PenAlirocumab29$19,254
JardianceEmpagliflozin17$10,442
JanuviaSitagliptin Phosphate12$6,081
Hydrocortisone38$1,306
FenofibrateFenofibrate,micronized13$549
Topiramate79$536
Rosuvastatin Calcium27$445
Levothyroxine Sodium45$341
Alendronate Sodium19$223
Atorvastatin Calcium12$62
Glipizide12$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$7,471$52,88741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.

Other endocrinology, diabetes & metabolism in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →